Published in Semin Radiat Oncol on January 01, 2006
Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res (2008) 1.58
Targeting inflammatory pathways for tumor radiosensitization. Biochem Pharmacol (2010) 1.22
CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle. Mol Interv (2011) 1.14
A reevaluation of X-irradiation-induced phocomelia and proximodistal limb patterning. Nature (2009) 1.10
Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms. Breast Cancer Res (2010) 1.03
Effects of tumor-suppressor lysyl oxidase propeptide on prostate cancer xenograft growth and its direct interactions with DNA repair pathways. Oncogene (2014) 0.91
A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe. Invest New Drugs (2009) 0.86
Targeted inhibition of mammalian target of rapamycin (mTOR) enhances radiosensitivity in pancreatic carcinoma cells. Drug Des Devel Ther (2013) 0.84
DW-MRI as a Predictive Biomarker of Radiosensitization of GBM through Targeted Inhibition of Checkpoint Kinases. Transl Oncol (2013) 0.83
Altering the response to radiation: sensitizers and protectors. Semin Oncol (2014) 0.81
Molecular imaging of the ATM kinase activity. Int J Radiat Oncol Biol Phys (2013) 0.80
Interferon-gamma enhances radiation-induced cell death via downregulation of Chk1. Cancer Biol Ther (2012) 0.80
Perspectives in cell cycle regulation: lessons from an anoxic vertebrate. Curr Genomics (2009) 0.80
Effect of X-Irradiation at Different Stages in the Cell Cycle on Individual Cell-Based Kinetics in an Asynchronous Cell Population. PLoS One (2015) 0.78
Hypoxia-Inducible Factor-1: A Critical Player in the Survival Strategy of Stressed Cells. J Cell Biochem (2016) 0.78
Kinase-independent role for CRAF-driving tumour radioresistance via CHK2. Nat Commun (2015) 0.77
A comprehensive analysis of radiosensitization targets; functional inhibition of DNA methyltransferase 3B radiosensitizes by disrupting DNA damage regulation. Sci Rep (2015) 0.76
Temporo-spatial cell-cycle kinetics in HeLa cells irradiated by Ir-192 high dose-rate remote afterloading system (HDR-RALS). Radiat Oncol (2016) 0.75
Increased chemosensitivity and radiosensitivity of human breast cancer cell lines treated with novel functionalized single-walled carbon nanotubes. Oncol Lett (2016) 0.75
HBXIP, a binding protein of HBx, regulates maintenance of the G2/M phase checkpoint induced by DNA Damage and enhances sensitivity to doxorubicin-induced cytotoxicity. Cell Cycle (2017) 0.75
Overexpression of Rad51 Predicts Poor Prognosis in Colorectal Cancer: Our Experience with 54 Patients. PLoS One (2017) 0.75
Biological mechanisms of gold nanoparticle radiosensitization. Cancer Nanotechnol (2017) 0.75
Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol (2002) 3.08
Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res (2010) 2.68
Down-regulation of Rad51 and decreased homologous recombination in hypoxic cancer cells. Mol Cell Biol (2004) 2.09
Hypoxia-induced down-regulation of BRCA1 expression by E2Fs. Cancer Res (2005) 2.02
Inverse relationship between biochemical outcome and acute toxicity after image-guided radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2011) 2.00
Gold nanoparticles as radiation sensitizers in cancer therapy. Radiat Res (2010) 1.97
MRE11 promotes AKT phosphorylation in direct response to DNA double-strand breaks. Cell Cycle (2011) 1.97
Ionizing radiation activates AMP-activated kinase (AMPK): a target for radiosensitization of human cancer cells. Int J Radiat Oncol Biol Phys (2010) 1.89
Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res (2008) 1.70
Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. J Clin Invest (2012) 1.57
PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin Cancer Res (2011) 1.46
TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. Clin Cancer Res (2013) 1.45
MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res (2010) 1.44
Promyelocytic leukemia nuclear bodies behave as DNA damage sensors whose response to DNA double-strand breaks is regulated by NBS1 and the kinases ATM, Chk2, and ATR. J Cell Biol (2006) 1.43
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J Pathol (2012) 1.42
A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother Oncol (2008) 1.39
The MMS22L-TONSL complex mediates recovery from replication stress and homologous recombination. Mol Cell (2010) 1.32
Novel chemical enhancers of heat shock increase thermal radiosensitization through a mitotic catastrophe pathway. Cancer Res (2007) 1.32
The p53 protein family and radiation sensitivity: Yes or no? Cancer Metastasis Rev (2004) 1.24
Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin Cancer Res (2013) 1.24
Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy. Cancer (2012) 1.23
Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother Oncol (2005) 1.22
Treatment of radiation proctitis with hyperbaric oxygen. Radiother Oncol (2005) 1.18
Late residual gamma-H2AX foci in murine skin are dose responsive and predict radiosensitivity in vivo. Radiat Res (2010) 1.17
Evidence for the direct binding of phosphorylated p53 to sites of DNA breaks in vivo. Cancer Res (2005) 1.16
Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies. Future Oncol (2007) 1.15
Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin Radiat Oncol (2010) 1.14
Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression. Cancer Res (2004) 1.13
Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: a pilot study in men with prostate cancer. Int J Radiat Biol (2009) 1.13
Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents. J Clin Oncol (2003) 1.11
Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Mol Cancer Ther (2009) 1.11
"Contextual" synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair. Clin Cancer Res (2010) 1.11
High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate (2009) 1.08
Microscopic imaging of DNA repair foci in irradiated normal tissues. Int J Radiat Biol (2009) 1.08
Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. J Pathol (2012) 1.07
Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther (2008) 1.03
Tumor cell kill by c-MYC depletion: role of MYC-regulated genes that control DNA double-strand break repair. Cancer Res (2010) 1.02
miRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1. Cancer Res (2013) 1.02
Analysis of variants in DNA damage signalling genes in bladder cancer. BMC Med Genet (2008) 0.99
Inhibition of breast cancer local relapse by targeting p70S6 kinase activity. J Mol Cell Biol (2013) 0.99
Discordance between phosphorylation and recruitment of 53BP1 in response to DNA double-strand breaks. Cell Cycle (2012) 0.98
NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy. Clin Cancer Res (2011) 0.96
Alterations in DNA repair gene expression under hypoxia: elucidating the mechanisms of hypoxia-induced genetic instability. Ann N Y Acad Sci (2005) 0.96
Ionizing radiation regulates the expression of AMP-activated protein kinase (AMPK) in epithelial cancer cells: modulation of cellular signals regulating cell cycle and survival. Radiother Oncol (2012) 0.95
PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status. Radiother Oncol (2008) 0.94
Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: clinical and translational issues. Cancer (2005) 0.94
DNA repair targeting and radiotherapy: a focus on the therapeutic ratio. Semin Radiat Oncol (2010) 0.93
Longitudinal cytokine expression during IMRT for prostate cancer and acute treatment toxicity. Clin Cancer Res (2009) 0.92
Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways. Radiat Oncol (2011) 0.92
Direct observation of ultrafast-electron-transfer reactions unravels high effectiveness of reductive DNA damage. Proc Natl Acad Sci U S A (2011) 0.92
Chronic hypoxia compromises repair of DNA double-strand breaks to drive genetic instability. J Cell Sci (2012) 0.92
ShatterProof: operational detection and quantification of chromothripsis. BMC Bioinformatics (2014) 0.91
Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer. Nat Rev Clin Oncol (2010) 0.88
Inherently multimodal nanoparticle-driven tracking and real-time delineation of orthotopic prostate tumors and micrometastases. ACS Nano (2013) 0.88
Intratumoral hypoxia as the genesis of genetic instability and clinical prognosis in prostate cancer. Adv Exp Med Biol (2014) 0.87
Radiation effects and radioprotection in MC3T3-E1 mouse calvarial osteoblastic cells. Plast Reconstr Surg (2008) 0.87
Hypoxia disrupts the Fanconi anemia pathway and sensitizes cells to chemotherapy through regulation of UBE2T. Radiother Oncol (2011) 0.86
Education and training for radiation scientists: radiation research program and American Society of Therapeutic Radiology and Oncology Workshop, Bethesda, Maryland, May 12-14, 2003. Radiat Res (2003) 0.86
Molecular markers predicting radiotherapy response: report and recommendations from an International Atomic Energy Agency technical meeting. Int J Radiat Oncol Biol Phys (2005) 0.86
Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol (2007) 0.86
Imatinib radiosensitizes bladder cancer by targeting homologous recombination. Cancer Res (2013) 0.86
Biomarkers for DNA DSB inhibitors and radiotherapy clinical trials. Cancer Metastasis Rev (2008) 0.86
High tumor interstitial fluid pressure identifies cervical cancer patients with improved survival from radiotherapy plus cisplatin versus radiotherapy alone. Int J Cancer (2014) 0.85
Primary esophageal and gastro-esophageal junction cancer xenograft models: clinicopathological features and engraftment. Lab Invest (2013) 0.85
Practical approaches to proteomic biomarkers within prostate cancer radiotherapy trials. Cancer Metastasis Rev (2008) 0.84
Protein-protein interactions occur between p53 phosphoforms and ATM and 53BP1 at sites of exogenous DNA damage. Radiat Res (2011) 0.84
WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells. Mol Cancer Ther (2008) 0.84
The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination. Radiother Oncol (2011) 0.84
Radiation Therapy Oncology Group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trials. Int J Radiat Oncol Biol Phys (2009) 0.83
AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells. Int J Radiat Oncol Biol Phys (2012) 0.83
Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer. Acta Oncol (2010) 0.83
Detection of genetic instability at HER-2/neu and p53 loci in breast cancer cells sing Comet-FISH. Breast Cancer Res Treat (2005) 0.82
Pathological predictors for site of local recurrence after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2012) 0.82
Electron transfer-based combination therapy of cisplatin with tetramethyl-p-phenylenediamine for ovarian, cervical, and lung cancers. Proc Natl Acad Sci U S A (2012) 0.81
Asthma in underserved schoolchildren in Miami, Florida: results of a school- and community-based needs assessment. J Asthma (2013) 0.81
Hypoxia and cellular localization influence the radiosensitizing effect of gold nanoparticles (AuNPs) in breast cancer cells. Radiat Res (2014) 0.81
Investigations of antioxidant-mediated protection and mitigation of radiation-induced DNA damage and lipid peroxidation in murine skin. Int J Radiat Biol (2013) 0.80
4FISH-IF, a four-color dual-gene FISH combined with p63 immunofluorescence to evaluate NKX3.1 and MYC status in prostate cancer. J Histochem Cytochem (2013) 0.80
A phase I trial of pre-operative radiotherapy for prostate cancer: clinical and translational studies. Radiother Oncol (2008) 0.80
Allelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancer. Prostate (2011) 0.80
WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathol Commun (2014) 0.79
In situ DNA repair assays as guides to personalized breast cancer chemotherapeutics: ready for prime time? J Clin Oncol (2011) 0.79
Tumor hypoxia as a modifier of DNA strand break and cross-link repair. Curr Mol Med (2009) 0.79
Overview of cancer molecular radiobiology. Cancer Treat Res (2008) 0.79
Corrigendum: analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat Genet (2015) 0.79
A role for p53 in the response of bystander cells to receipt of medium borne signals from irradiated cells. Int J Radiat Biol (2011) 0.78
Tumor senescence and radioresistant tumor-initiating cells (TICs): let sleeping dogs lie! Breast Cancer Res (2010) 0.78
The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers. Can Urol Assoc J (2011) 0.78
Biodosimetry using radiation-induced micronuclei in skin fibroblasts. Int J Radiat Biol (2011) 0.77
Clonality of localized and metastatic prostate cancer. Curr Opin Urol (2016) 0.77
Expression of different mutant p53 transgenes in neuroblastoma cells leads to different cellular responses to genotoxic agents. Exp Cell Res (2002) 0.76
Introduction: DNA repair and radiotherapy targeting: an overview. Semin Radiat Oncol (2010) 0.76
Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model. Mol Pharm (2014) 0.76
ATM-dependent phosphorylation of 53BP1 in response to genomic stress in oxic and hypoxic cells. Radiother Oncol (2011) 0.76
Prolonged survival in a patient with choroidal metastases from urothelial bladder cancer. Can Urol Assoc J (2009) 0.75
In reply to Nieder. Int J Radiat Oncol Biol Phys (2013) 0.75
Hypoxia, androgen deprivation and systemic metastases in prostate cancer (in response to "Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxitivity dynamic MRI": in regard to Alonzi R et al. (Int J Radiat Oncol Biol Phys 2011;80(3):721-727). Int J Radiat Oncol Biol Phys (2012) 0.75
Re: Vikram, B., The PSA conundrum. [Radiother Oncol, 2004. 71(1): p. 1-2]. Radiother Oncol (2004) 0.75